title: Intra-operative mitomycin C for glaucoma surgery.
abstract: BACKGROUND
  Trabeculectomy is performed as a treatment for glaucoma to lower the intraocular pressure (IOP). Mitomycin C (MMC) is an antimetabolite used during the initial stages of a trabeculectomy to prevent excessive postoperative scarring and thus reduce the risk of failure.
  
  
  OBJECTIVE
  To assess the effects of intraoperative MMC compared to placebo in trabeculectomy.
  
  
  METHODS
  We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group Trials Register) on The Cochrane Library (Issue 1, 2005), MEDLINE (1966 to March 2005), EMBASE (1985 to 20 March 2005), SIGLE (1980 to December 2004), the National Research Register (Issue 1, 2005), LILACS (29 March 2005) and reference lists of articles. We also contacted researchers in the field.
  
  
  METHODS
  We included randomised trials of intraoperative MMC compared to placebo in trabeculectomy surgery.
  
  
  METHODS
  Two authors independently assessed trial quality and extracted data. We contacted trial investigators for missing information.
  
  
  RESULTS
  Eleven trials, involving a total of 698 participants, were included. The trials enrolled three types of participants (high risk of failure, trabeculectomy combined with cataract surgery, no previous surgical intervention). Mitomycin C appears to reduce the relative risk of failure of trabeculectomy both in eyes at high risk of failure (relative risk 0.32, 95% confidence interval 0.20 to 0.53) and those undergoing surgery for the first time (relative risk 0.29, 95% confidence interval 0.16 to 0.53). No significant effect on failure was noted in the group undergoing trabeculectomy combined with cataract extraction. Mean IOP was significantly reduced at 12 months in all three participant groups receiving MMC compared to placebo. No significant increase in permanent sight-threatening complications was detected. However, none of the trials were large enough or of sufficient duration to address the long-term risk of bleb infection and endophthalmitis which has been reported in observational studies. Some evidence exists that MMC increases the risk of cataract.
  
  
  CONCLUSIONS
  Intraoperative MMC reduces the risk of surgical failure in eyes that have undergone no previous surgery and in eyes at high risk of failure. Compared to placebo it reduces mean IOP at 12 months in all groups of participants in this review. Apart from an increase in cataract formation following MMC, there was insufficient power to detect any increase in other serious side effects such as endophthalmitis.
authors.affiliation: Moorfields Eye Hospital, City Road, London, UK EC1V 2PD. mail@markwilkins.co.uk
authors.forename: M
authors.initials: M
authors.lastname: Wilkins
authors.forename: A
authors.initials: A
authors.lastname: Indar
authors.forename: R
authors.initials: R
authors.lastname: Wormald
mesh_terms: D000963:Antimetabolites / Q000009:adverse effects / Q000627:therapeutic use*; D002921:Cicatrix / Q000517:prevention & control*; D005901:Glaucoma / Q000601:surgery*; D006801:Humans; D007432:Intraoperative Period; D016685:Mitomycin / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D014130:Trabeculectomy / Q000009:adverse effects*; D017211:Treatment Failure
chemical_list: D000963:Antimetabolites; D016685:Mitomycin